IRLAB Therapeutics AB Class A · OMXSTO:IRLAB_A
IRLAB Therapeutics AB Class A — Q1 2022 Earnings Presentation
21 slides from IRLAB Therapeutics AB Class A's earnings presentation, May 2022
Slide 1: Transforming life for people with Parkinson's - Interim report Q1 2022
re IRLAB Transforming life for people with Parkinson’s Interim report Q1 2022 Pe IRLAB
Slide 2: Disclaimer
Disclaimer This document, “IRLAB Therapeutics” (the “Presentation”), has been prepared by IRLAB Therapeutics AB (publ) (“IRLAB”) and is provided for informational purposes only. All information in this Presentation has been compiled in good faith by IRLAB. Neither IRLAB nor any of its directors, emp
Slide 3: IRLAB: Accelerating development and growth
IRLAB: Accelerating development and growth Strong development of operations, strong cash position enabling investment in pipeline In partnership with a global pharma company Two programs with exciting prospects in clinical Phase IIb development Preclinical development candidates towards clinical Pha
Slide 4: Financial summary of Q1 2022
Financial summary of Q1 2022 Highlights * SEK 368m in cash January-March 2022 Compared with January-March and full year 2021 Jan-Mar 2022 Jan-Mar 2021 Comment on Q12022 Jan-Dec 2021 Net sales 9,042 0 207,782 Operating profits/loss -29,088 -19,967 52,576 . Net sales about SEK 7m Profit/loss for the p
Slide 5: • • • • Q1 2018 Q2 Q3 Q4 Q1 2019 Q2 Q3 Q4
• • • • 0 5 10 20 30 15 25 35 Q1 2018 Q2 Q3 Q4 Q1 2019 Q2 Q3 Q4 Q1 2020 Q2 Q3 Q4 Q1 2021 Q2 Q3 Q4 Q1 2022
Slide 6: Mesdopetam licensing pays off - investing in pipeline
Mesdopetam licensing pays off - investing in pipeline IRLAB following its strategy to become a next level business-oriented company * Innovative R&D * Expanded clinical operations + Professional IR and business development Comment on Q12022 Operational focus Mesdopetam Phase IIb - Focus on study com
Slide 7: Portfolio transforming treatments in Parkinson's and beyond
Comment on Portfolio transforming treatments in 12022 Parkinson’s and beyond PRE- CLINICAL | PHASE! | PHASEIla | PHASENIb | PHASE! DISCOVERY Mesdopetam * __ Partnering strategy antagonist PARKINSON - LEVODOPA-INDUCED DYSKINESIAS| | + 2021: partnered with (LIDS) SIPSEN + IPSENina global MESDOPETAM® P
Slide 8: Strong development newsflow 2022-2024
Strong development newsflow 2022-2024 Mesdopetam H2-22 Mesdopetam Phase Ilb LIDs top-line results Px IRLAB Pirepemat Pirepemat IIb study start Pirepemat Phase Ilb top-line results Pirepemat Phase Ill study start Comment on Q12022 IRL757 IRL757 through preclinical dev IRL757 Phase | study start IRL75
Slide 9: Preclinical development: IRL942, IRL757 and the P003 project
re IRLAB Preclinical development: IRL942, IRL757 and the POO3 project IRL942 Toimprove cognitive function & brain health IRL757_—- To treat apathy in neurology (Target populations: Parkinson’s, dementias, schizophrenia, depression) POO3 _—_Long-acting Parkinson’s treatment Efficacy equivalent to lev
Slide 10: IRL942: to improve cognitive function and brain health in neurological indications
IRL942: to improve cognitive function and brain health in neurological indications IRL942 opportunity * 12 % of adults aged 65 years or more experience cognitive decline (CDC) Problem ¢ Disruption of frontal neurocircuits are implicated in the pathogenesis of cognitive decline IRLAB’s solution + IRL
Slide 11: IRL757: to treat apathy in neurological indications
IRL757: to treat apathy in neurological indications IRL757 opportunity * Over 10 million US and EU citizens each may be affected by apathy * Apathy occurs in 20-70% in people with Parkinson’s and in 20-90% of people with Alzheimer’s and other CNS disorders Pathophysiological background * Disruption
Slide 12: P003: next generation Parkinson's treatments
POO3: next generation Parkinson’s treatments Objective: long-acting, orally available, Current standard-of-care (L-DOPA) POO3 objective treatment of core motor symptoms of Parkinson’s disease ° Excessive * Total market (16 largest regions): 8.3 million g response people diagnosed with PD in 2022 3 O
Slide 13: Pirepemat (IRL752)
re IRLAB Pirepemat (IRL752) To improve balance and reduce falls in Parkinson’s (PD-Falls) 73 TRLAB i
Slide 14: Pirepemat
Pirepemat Pirepemat is designed to improve balance and reduce falls in Parkinson’s PD-Falls patient population - A large unmet need (DE, ay 2 Ir, « 45% of all people with Parkinson’s fall ts eg recurrently 565,000 JR * Impaired balance and a fear of falling 470,000 395,000 | 275,000 | significantly
Slide 15: Pirepemat development during the first quarter
Pirepemat Pirepemat development during the first quarter 2022 Primary objective of the Phase Ilb study ¢ Evaluate the effects of pirepemat on falls frequency as compared to placebo Development during the first quarter 2022 * Regulatory approvals obtained in all countries participating Q4-21 and Q1-2
Slide 16: Mesdopetam (IRL790)
re IRLAB Mesdopetam (IRL790) To improve motor function through prevention and reduction of dyskinesias (LIDs) Treatment and prevention of psychosis in Parkinson’s (PD-P) 3 TRLAB Currently in development with partner Ipsen who holds an exclusive global license to develop and commercialize mesdopetam
Slide 17: Mesdopetam
Mesdopetam Parkinson’s disease levodopa-induced dyskinesia - an unmet need PD-LIDs patients globall Developments in Q1 F e y * Study enrollment continues with a strong focus on completion of the study oe ee ar * Noticeable impact of Covid 19 during the beginning iy of the quarter us 230 000 JP. * Pr
Slide 18: Mesdopetam
Mesdopetam Wide clinical potential in unmet medical needs in neurology PD-LIDs PD-P Levodopa-induced dyskinesias Parkinson's disease psychosis LD) Tardive dyskinesia Affects about 25% of patients + Affects about 35% of patients with Parkinson’s with Parkinson’s, often associated Few treatment option
Slide 19: Path to deliver strong growth
Path to deliver strong growth Foundation for transformative treatments 2020 - 2023 Mesdopetam Successful completion of Phase IIb/III study* Pirepemat Successful completion of Phase IIb study Pipeline Initiate Phase | studies with IRL942 and IRL757 Initiate preclinical development of CD from P003 Dee
Slide 20: Q&A
Q&A
Slide 21: Contact
aul IRLAB Contact: Viktor Siewertz, CFO, [email protected], Nicholas Waters, CEO, [email protected], IRLAB discovers and develops novel drugs for the treatment of Parkinson’s disease and other disorders of the brain. The company’s most advanced drug candidates, mesdopetam (IRL790) and